Sanofi SA (NYSE: SNY)is in the midst of a transition that it hopes will return it to business income growth in 2019. The French biopharma is one of the biggest drugmakers in the world, but its shares have suffered lately because of patent expiration. Is now a good time to pick this stock up on sale?
Is This European Drug Stock Giant a Buy?
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться